Adherence to long-term non-invasive positive airway pressure therapy.

Autor: Staehr-Rye AK; Respiratory Center East, Department of Anaesthesia, Pain, and Respiratory Support, Copenhagen University Hospital - Rigshospitalet - Glostrup.; Department of Clinical Medicine, University of Copenhagen, Denmark., Irlind TØ; Respiratory Center East, Department of Anaesthesia, Pain, and Respiratory Support, Copenhagen University Hospital - Rigshospitalet - Glostrup., Funderskov K; Respiratory Center East, Department of Anaesthesia, Pain, and Respiratory Support, Copenhagen University Hospital - Rigshospitalet - Glostrup., Gätke MR; Respiratory Center East, Department of Anaesthesia, Pain, and Respiratory Support, Copenhagen University Hospital - Rigshospitalet - Glostrup., Küchen SHL; Respiratory Center East, Department of Anaesthesia, Pain, and Respiratory Support, Copenhagen University Hospital - Rigshospitalet - Glostrup.
Jazyk: angličtina
Zdroj: Danish medical journal [Dan Med J] 2024 Oct 25; Vol. 71 (11). Date of Electronic Publication: 2024 Oct 25.
DOI: 10.61409/A04240290
Abstrakt: Introduction: Studies have shown varying patient adherence to long-term non-invasive positive airway pressure therapy (nPAP). We aimed to investigate adherence to long-term nPAP in a Danish cohort of patients with chronic respiratory insufficiency and/or sleep-disordered breathing (SDB) due to neuromuscular disorders (NMD), obesity-hypoventilation syndrome (OHS) or other reasons.
Methods: This cohort study included all adult patients with association to the Respiratory Center East treated with long-term nPAP: bilevel (BiPAP), automatic (APAP) and continuous (CPAP) or adaptive servo-ventilation (ASV) with a remote monitoring system in April 2022. The primary outcome was adherence, defined as a median use of nPAP ≥ 4 hrs/day in April 2022. A preplanned extended subgroup analysis was conducted for patients with data on adherence from initiation and six months onwards.
Results: The primary analysis included 241 patients, of whom 90% were diagnosed with NMD (54%) or OHS (36%). The nPAP was used ≥ 4 hrs/day by 175 patients (73%), including 22 (100%) with ASV, 129 (72%) with BiPAP and 24 (59%) with APAP/CPAP. Treatment adherence was seen in 75% of patients with NMD, 64% with OHS and 84% with other reasons for SDB. The proportion of adherent subjects in the subgroup analysis of 55 patients was relatively stable throughout the six-month period, ranging from 67% to 75% with slight intraindividual variation.
Conclusion: In this retrospective analysis of adults primarily with NMD and OHS, 73% used the prescribed nPAP therapy ≥ 4 hrs/day.
Funding: None TRIAL REGISTRATION.
Clinicaltrials: gov(NCT05379309).
(Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Databáze: MEDLINE